Off-Label Drug Use and Fda Review of Supplemental Drug Applications
Hearing Before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, Second Session; September 12, 1996
Price for Eshop: 241 Kč (€ 9.6)
VAT 0% included
New
E-book delivered electronically online
E-Book information
Annotation
Whilst the greatest effort has been made to ensure the quality of this text, due to the historical nature of this content, in some rare cases there may be minor issues with legibility. Pervasive off-label use can blur the distinction between medical information and drug promotion, as pharmaceutical developers, with neither financial nor regulatory incentives to undertake costly supplemental studies, find ways to spread the word on off-label uses of their products.
Ask question
You can ask us about this book and we'll send an answer to your e-mail.